1
|
Gonçalves Â, Matias M, Salvador JAR, Silvestre S. Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use? Int J Mol Sci 2024; 25:1600. [PMID: 38338879 PMCID: PMC10855265 DOI: 10.3390/ijms25031600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open
Abstract
Bismuth compounds are considered relatively non-toxic, with their low solubility in aqueous solutions (e.g., biological fluids) being the major contributing factor to this property. Bismuth derivatives are widely used for the treatment of peptic ulcers, functional dyspepsia, and chronic gastritis. Moreover, the properties of bismuth compounds have also been extensively explored in two main fields of action: antimicrobial and anticancer. Despite the clinical interest of bismuth-based drugs, several side effects have also been reported. In fact, excessive acute ingestion of bismuth, or abuse for an extended period of time, can lead to toxicity. However, evidence has demonstrated that the discontinuation of these compounds usually reverses their toxic effects. Notwithstanding, the continuously growing use of bismuth products suggests that it is indeed part of our environment and our daily lives, which urges a more in-depth review and investigation into its possible undesired activities. Therefore, this review aims to update the pharmaco-toxicological properties of bismuth compounds. A special focus will be given to in vitro, in vivo, and clinical studies exploring their toxicity.
Collapse
Affiliation(s)
- Ângela Gonçalves
- CICS-UBI—Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal; (Â.G.); (M.M.)
| | - Mariana Matias
- CICS-UBI—Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal; (Â.G.); (M.M.)
| | - Jorge A. R. Salvador
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal;
- CNC—Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
| | - Samuel Silvestre
- CICS-UBI—Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal; (Â.G.); (M.M.)
- CNC—Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
| |
Collapse
|
2
|
Effects of Bismuth Exposure on the Human Kidney-A Systematic Review. Antibiotics (Basel) 2022; 11:antibiotics11121741. [PMID: 36551397 PMCID: PMC9774474 DOI: 10.3390/antibiotics11121741] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 11/23/2022] [Accepted: 11/30/2022] [Indexed: 12/09/2022] Open
Abstract
The effects of bismuth toxicity on the kidney-the main organ responsible for blood filtration-were systematically reviewed. This review was motivated by availability of several sources of bismuth in contact with humans including environmental, medications, dental materials, and cosmetics, potentially leading to kidney filtration of this chemical. No previous studies have systematically reviewed the literature considering this association. A total of 22 studies with a total of 46 individuals met the inclusion criteria, 19 being case reports with only one patient enrolled. The included studies publication dates ranged from 1961 to 2021 and the countries of publication were the United States of America, United Kingdom, Germany, Turkey, Switzerland, and Canada. Bismuth sources affecting the kidneys were uniquely reported as from medical purposes and mostly associated to overdoses with several symptoms, apparently with dose-dependent consequences. Patient history of renal impairment seemed to affect the outcome of the case. Several therapies were conducted following bismuth intoxication, and few studies performed renal biopsies describing its histological findings. It is crucial to reconsider the nephrotoxicity of bismuth compounds, mainly in patients with previous history of renal impairment.
Collapse
|
3
|
Wang R, Chan JFW, Wang S, Li H, Zhao J, Ip TKY, Zuo Z, Yuen KY, Yuan S, Sun H. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chem Sci 2022; 13:2238-2248. [PMID: 35310492 PMCID: PMC8864717 DOI: 10.1039/d1sc04515f] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 11/24/2021] [Indexed: 12/20/2022] Open
Abstract
A cocktail therapy comprising bismuth drugs and N-acetyl-l-cysteine is reported to suppress the replication of SARS-CoV-2 via the oral route. The broad-spectrum inhibitory activities of the combination upon key viral cysteine enzymes are verified.
Collapse
Affiliation(s)
- Runming Wang
- Department of Chemistry, CAS-HKU Joint Laboratory of Metallomics on Health and Environment, The University of Hong Kong, Hong Kong SAR, P. R. China
| | - Jasper Fuk-Woo Chan
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
- Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China
- Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
- Academician Workstation of Hainan Province, Hainan Medical University, Haikou, Hainan, China
- Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China
| | - Suyu Wang
- Department of Chemistry, CAS-HKU Joint Laboratory of Metallomics on Health and Environment, The University of Hong Kong, Hong Kong SAR, P. R. China
| | - Hongyan Li
- Department of Chemistry, CAS-HKU Joint Laboratory of Metallomics on Health and Environment, The University of Hong Kong, Hong Kong SAR, P. R. China
| | - Jiajia Zhao
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
| | - Tiffany Ka-Yan Ip
- Department of Chemistry, CAS-HKU Joint Laboratory of Metallomics on Health and Environment, The University of Hong Kong, Hong Kong SAR, P. R. China
| | - Zhong Zuo
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
| | - Kwok-Yung Yuen
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
- Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China
- Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
- Academician Workstation of Hainan Province, Hainan Medical University, Haikou, Hainan, China
- Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China
| | - Shuofeng Yuan
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
- Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China
- Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR, China
| | - Hongzhe Sun
- Department of Chemistry, CAS-HKU Joint Laboratory of Metallomics on Health and Environment, The University of Hong Kong, Hong Kong SAR, P. R. China
| |
Collapse
|
4
|
Xinjie Y, Yan L. Effect of modified Sanhuang Xiexin Tang plus additional herbs combined with “standard triple therapy” on Helicobacter pylori eradication. J TRADIT CHIN MED 2018. [DOI: 10.1016/j.jtcm.2018.02.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
5
|
Akinci E, Köylü R, Yortanli M, Gümüş H, Köylü Ö, Altintepe L, Cander B. Acute Bismuth Intoxication: Acute Renal Failure, Tonsillar Ulceration and Posterior Reversible Encephalopathy Syndrome. HONG KONG J EMERG ME 2017. [DOI: 10.1177/102490791502200208] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Consumption and production of bismuth compounds are increasing, however, little information on the toxic effects and effective methods in removal of bismuth compounds are available. Although bismuth intoxication is currently rare, a careful evaluation should be carried out for possible exposure. We reported a16-year-old female who developed acute kidney failure, tonsillar ulceration and posterior reversible encephalopathy syndrome after an ingestion of 19 grams of bismuth subcitrate for suicidal attempt. (Hong Kong j.emerg.med. 2015;22:121-125)
Collapse
Affiliation(s)
- E Akinci
- Konya Training and Research Hospital, Neurology Department, Hacl Şaban Mahallesi, Meram Yeniyol Caddesi No:97, 42090 Meram/Konya, Turkey
| | - R Köylü
- Konya Training and Research Hospital, Neurology Department, Hacl Şaban Mahallesi, Meram Yeniyol Caddesi No:97, 42090 Meram/Konya, Turkey
| | - M Yortanli
- Konya Training and Research Hospital, Neurology Department, Hacl Şaban Mahallesi, Meram Yeniyol Caddesi No:97, 42090 Meram/Konya, Turkey
| | - H Gümüş
- Konya Training and Research Hospital, Neurology Department, Hacl Şaban Mahallesi, Meram Yeniyol Caddesi No:97, 42090 Meram/Konya, Turkey
| | - Ö Köylü
- Konya Training and Research Hospital, Neurology Department, Hacl Şaban Mahallesi, Meram Yeniyol Caddesi No:97, 42090 Meram/Konya, Turkey
| | - L Altintepe
- Konya Training and Research Hospital, Neurology Department, Hacl Şaban Mahallesi, Meram Yeniyol Caddesi No:97, 42090 Meram/Konya, Turkey
| | | |
Collapse
|
6
|
Roth AK, Boon-Ceelen K, Smelt H, van Rietbergen B, Willems PC, van Rhijn LW, Arts JJ. Radiopaque UHMWPE sublaminar cables for spinal deformity correction: Preclinical mechanical and radiopacifier leaching assessment. J Biomed Mater Res B Appl Biomater 2017; 106:771-779. [PMID: 28346744 DOI: 10.1002/jbm.b.33886] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 02/24/2017] [Accepted: 03/12/2017] [Indexed: 11/07/2022]
Abstract
Polymeric sublaminar cables have a number of advantages over metal cables in the field of spinal deformity surgery, with decreased risk of neurological injury and potential for higher correction forces as the two most predominant. However, currently available polymer cables are radiolucent, precluding postoperative radiological assessment of instrumentation stability and integrity. This study provides a preclinical assessment of a woven UHMWPE cable made with radiopaque UHMWPE fibers. Our primary goal was to determine if the addition of a radiopacifier negatively affects the mechanical properties of UHMWPE woven cables. Tensile mechanical properties were determined and compared to suitable controls. Radiopacity was evaluated and radiopacifier leaching was assessed in vitro and in vivo. Finally, in vivo bismuth organ content was quantified after a 24-week implantation period in sheep. Results show that the mechanical properties of woven UHMWPE cables were not deleteriously affected by the addition of homogenously dispersed bismuth oxide particles within each fiber. Limited amounts of bismuth oxide were released in vitro, well below the toxicological threshold. Tissue concentrations lower than generally accepted therapeutic dosages for use against gastrointestinal disorders, well below toxic levels, were discovered in vivo. These results substantiate controlled clinical introduction of these radiopaque UHMWPE cables. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 771-779, 2018.
Collapse
Affiliation(s)
- Alex K Roth
- Department of Orthopaedic Surgery, Research School CAPHRI, Maastricht University Medical Center, Maastricht, the Netherlands
| | | | | | - Bert van Rietbergen
- Orthopaedic Biomechanics, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Paul C Willems
- Department of Orthopaedic Surgery, Research School CAPHRI, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Lodewijk W van Rhijn
- Department of Orthopaedic Surgery, Research School CAPHRI, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Jacobus J Arts
- Department of Orthopaedic Surgery, Research School CAPHRI, Maastricht University Medical Center, Maastricht, the Netherlands
| |
Collapse
|
7
|
Saleem A, Qasim A, O'Connor HJ, O'Morain CA. Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther 2009; 7:793-9. [PMID: 19735221 DOI: 10.1586/eri.09.55] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
An ideal antibiotic regimen for Helicobacter pylori should achieve eradication rates of approximately 90%. Current 7-day triple therapy is successful in about two-thirds of patients. A novel treatment is required to achieve higher eradication with minimal induction of bacterial resistance. The aim of this article is to evaluate the safety and efficacy of a single triple capsule (Pylera) containing bismuth, metronidazole and tetracycline, given with omeprazole for the eradication of H. pylori infection. Extensive literature searches were conducted using PubMed data from 1982 to 2007. This search included headings of H. pylori, bismuth and eradication therapy. The triple capsule Pylera, when given with omeprazole, achieved eradication rates ranging between 84 and 97%. Eradication rates were similar for clarithromycin- and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable for metronidazole-resistant and -sensitive strains. This effect is not seen with the use of triple therapy in cases of clarithromycin resistance. Clinical trials did not report any serious side effects from bismuth-based regimens and compliance was similar to standard triple therapy. Bismuth-based triple therapy using Pylera is a simplified, effective and well-tolerated regimen achieving cure rates of above 90%.
Collapse
Affiliation(s)
- Aamir Saleem
- Adelaide and Meath Hospital, Incorporating the National Children's Hospital, Tallaght, Trinity College Dublin, Ireland.
| | | | | | | |
Collapse
|
8
|
Lee JW, Lin DJ, Ju CP, Yin HS, Chuang CC, Lin JHC. In-vitro and in-vivo evaluation of a new Ti-15Mo-1Bi alloy. J Biomed Mater Res B Appl Biomater 2009; 91:643-650. [PMID: 19630058 DOI: 10.1002/jbm.b.31440] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The newly developed Ti-15Mo-1Bi alloy not only possesses all the desirable mechanical properties inherent to beta-Ti Mo alloys, but may even enjoy better clinical applicability with the addition of bismuth element, which has long been administered as antibacterial and antitumor medicines. A significantly higher viability of 3T3 cells was demonstrated when they were grown on Ti-15Mo-1Bi alloy than on Ti-15Mo and Ti-6Al-4V. Cells incubated in the medium conditioned by Bi powder at 37 degrees C for 96 h exhibited viability similar to that in the blank group and higher than that in the Ni conditioned group. In vivo experiments using 6 mm x 2 mm metal pin implanted into the epicondyle of rabbit femur revealed superior potential of new bone growth and better persistence of the deposited bony tissue with the Ti-15Mo-1Bi alloy in contrast to that with Ti-6Al-4V. The difference is evident at 12th week and become even more prominent after 26 weeks, with the new bone area measuring 249% of that around Ti-6Al-4V alloy. In summary, Ti-15Mo-1Bi alloys show no cytotoxicity in the in-vitro test and demonstrates superior ability to retain bone in the in-vivo implantation experiment as compared with Ti-6Al-4V alloys.
Collapse
Affiliation(s)
- Jing-Wei Lee
- Division of Plastic Surgery, Department of Surgery, National Cheng-Kung University Medical College and Hospital, Tainan 704, Taiwan, Republic of China
| | - Dan-Jae Lin
- Department of Dental Hygiene, China Medical University, Taichung 404, Taiwan, Republic of China
| | - Chien-Ping Ju
- Department of Materials Science and Engineering, National Cheng-Kung University, Tainan 701, Taiwan, Republic of China
| | - Hsiang-Shu Yin
- Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei 100, Taiwan, Republic of China
| | - Cheng-Chung Chuang
- Department of Materials Science and Engineering, National Cheng-Kung University, Tainan 701, Taiwan, Republic of China
| | - Jiin-Huey Chern Lin
- Department of Materials Science and Engineering, National Cheng-Kung University, Tainan 701, Taiwan, Republic of China
| |
Collapse
|
9
|
Cengiz N, Uslu Y, Gök F, Anarat A. Acute renal failure after overdose of colloidal bismuth subcitrate. Pediatr Nephrol 2005; 20:1355-8. [PMID: 15947979 DOI: 10.1007/s00467-005-1993-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2005] [Revised: 04/21/2005] [Accepted: 04/25/2005] [Indexed: 10/25/2022]
Abstract
Bismuth salts are widely used to treat peptic ulcers. Acute toxicity with colloidal bismuth subcitrate overdose causes nephrotoxicity. There have been numerous reports of encephalopathy after long-term consumption of bismuth salts, but only a few cases of nephrotoxicity (adult and pediatric) have been documented to date. This report presents a case of acute renal failure due to colloidal bismuth subcitrate overdose in adolescent. A 16-year-old girl presented with complaints of nausea, vomiting, and facial paresthesia. Ten days earlier she had tried to commit suicide by taking 60 tablets of De-nol (colloidal bismuth subcitrate 18 g). The physical examination findings on admission indicated minimal fluid overload but no signs of encephalopathy. Laboratory tests on admission showed blood urea nitrogen 102 mg/dl, serum creatinine 19.9 mg/dl, and serum bismuth level 495 microg/l. The patient was started on appropriate fluid therapy and penicillamine as a chelating agent and then began hemodialysis on alternate days. The patient's renal function gradually returned to normal over 9 weeks and by 64 days after the overdose her serum bismuth level had fallen to almost half the level detected 2 days after admission. The patient made a complete recovery. The case demonstrates that acute renal failure can develop as a manifestation of acute toxicity from colloidal bismuth ingestion, and that the prognosis may be favorable if the patient receives appropriate supportive treatment and dialysis.
Collapse
Affiliation(s)
- Nurcan Cengiz
- Department of Pediatric Nephrology, Faculty of Medicine, Adana Teaching and Medical Research Center, Baskent University, 01140 Adana, Turkey.
| | | | | | | |
Collapse
|
10
|
Leussink BT, Nagelkerke JF, van de Water B, Slikkerveer A, van der Voet GB, Srinivasan A, Bruijn JA, de Wolff FA, de Heer E. Pathways of proximal tubular cell death in bismuth nephrotoxicity. Toxicol Appl Pharmacol 2002; 180:100-9. [PMID: 11969377 DOI: 10.1006/taap.2002.9379] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Colloidal bismuth subcitrate (CBS), a drug for treatment of peptic ulcers, has been reported in the literature to be nephrotoxic in humans when taken in high overdoses. To investigate the mechanism of bismuth nephropathy, we developed an animal model by feeding rats single doses of CBS containing 3.0 mmol Bi/kg body weight. Terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling assay, immunostaining for active caspase-3, and electron microscopy showed that proximal tubular epithelial cells die by necrosis and not by apoptosis within 3 h after CBS administration. Exposure of the renal epithelial cell lines NRK-52E and LLC-PK1 to Bi(3+) in citrate buffer served as an in vitro model of bismuth nephropathy. NRK-52E cells exposed to 100 microM Bi(3+) or more died by necrosis, as was demonstrated by nuclear staining with Hoechst 33258 and flow cytometry using Alexa(488)-labeled Annexin-V and the vital nuclear dye TOPRO-3. Bismuth-induced cell death of NRK-52E cells was not prevented by the caspase-3 inhibitor z-VAD-fmk, whereas this inhibitor did prevent cisplatinum-induced apoptosis. Mitochondrial dysfunction and induction of free radicals were shown not to be involved in bismuth nephrotoxicity. The early time point of damage induction in vitro as well as in vivo and the early displacement of N-cadherin, as found in previous studies, suggest that bismuth induces cell death by destabilizing the cell membrane. In conclusion, we showed that high overdose of bismuth induced cell death by necrosis in vivo as well as in vitro, possibly by destabilization of the cell membrane.
Collapse
Affiliation(s)
- Berend T Leussink
- Toxicology Laboratory, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Hruz P, Mayr M, Löw R, Drewe J, Huber G. Fanconi's syndrome, acute renal failure, and tonsil ulcerations after colloidal bismuth subcitrate intoxication. Am J Kidney Dis 2002; 39:E18. [PMID: 11877598 DOI: 10.1053/ajkd.2002.31429] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A 22-year-old woman ingested 5.4 g of colloidal bismuth subcitrate (CBS) in a suicide attempt. After ingestion, she presented with Fanconi's syndrome and acute renal failure to our unit. On the third day after ingestion, she was anuric. Ulcerations of both tonsils were observed 8 days after intoxication. Sodium-2,3-dimercapto-1-propanesulfonate (DMPS) is shown to be an effective chelating agent of heavy metal intoxications, but it has only a small effect on elimination of bismuth salts in patients with renal insufficiency without hemodialysis. In our case, we initiated hemodialysis and intravenous treatment with DMPS 60 hours after intoxication. By repeated measurements of bismuth concentrations in serum and dialyzed fluid, we showed its successful elimination. Serum bismuth level decreased from 640 microg/L to 15 microg/L within 6 days. With elimination of bismuth, renal function improved, and tonsil ulcerations healed. Hemodialysis was discontinued on day 14. Follow-up examination 6 weeks later showed normal renal function. Clinicians should be aware that acute renal failure and tonsil ulcerations can occur after CBS intoxication. Generally, acute renal failure caused by CBS intoxication is reversible. Treatment with the chelating agent DMPS in combination with hemodialysis is highly effective in reducing the serum bismuth level in patients with acute renal failure.
Collapse
Affiliation(s)
- Petr Hruz
- Department of Internal Medicine Clinic B, Division of Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
| | | | | | | | | |
Collapse
|
12
|
Leussink BT, Litvinov SV, de Heer E, Slikkerveer A, van der Voet GB, Bruijn JA, de Wolff FA. Loss of homotypic epithelial cell adhesion by selective N-cadherin displacement in bismuth nephrotoxicity. Toxicol Appl Pharmacol 2001; 175:54-9. [PMID: 11509026 DOI: 10.1006/taap.2001.9228] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The nephrotoxicity of single high doses of bismuth (Bi)-containing therapeutic drugs is characterized morphologically by detachment of proximal tubular epithelial cells (PTECs) from each other, followed by cell death. We investigated whether Bi nephrotoxicity is mediated by changes in the distribution of proteins involved in intercellular adhesion. A nephrotoxic dose of colloidal bismuth subcitrate (CBS; 3.0 mmol Bi/kg) was orally administrated to 10 female Wistar rats. After 1 h, N-cadherin had disappeared from the adherence junctions of vital PTECs, whereas ZO-1, a tight junction marker, remained present at the cell-cell border until cell death occurred after 3 h. E-Cadherin, absent in PTECs, remained absent. Exposure of the renal epithelial cell lines NRK-52E and LLC-PK1 to 400 microM Bi(3+) also resulted in the disappearance of N-cadherin expression after 1 h, whereas ZO-1, E-cadherin, and Desmoplakin expression did not resolve before cell death at 24 h, thus confirming in vivo results. Our results are the first to indicate that Bi-induced death of PTECs is preceded by redistribution of N-cadherin and the disruption of homotypic cell adhesion.
Collapse
Affiliation(s)
- B T Leussink
- Toxicology Laboratory, Leiden University Medical Center, Leiden, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Helicobacter pylori is now recognised to be typically acquired during childhood. Studies also indicate that the infection is frequently lost in childhood; however, it is still unclear whether this is related to the use of antibacterials, the natural history of the infection, or both. H. pylori colonises gastric mucosa and is causally related to chronic gastritis and peptic ulcer disease in both children and adults. Successful eradication of H. pylori has resulted in the healing of duodenal ulcers and the lowering of the ulcer relapse rate in children. Therapy to cure the infection should be started in all children with peptic (duodenal or gastric) ulcer who are still infected. The ideal anti-H. pylori regimen should be safe, cheap, easy to comply with, well tolerated by children and able to achieve a high cure rate. Although US data are lacking, it is anticipated that the treatment regimen for children should be similar to that in adults (a triple therapy regimen that combines a proton pump inhibitor with 2 antimicrobial agents for 14 days). It is inappropriate to prescribe anti-H. pylori therapy without a firm diagnosis. The use of multiple antibacterials in a paediatric patient with an ulcer but without H. pylori infection cannot provide any benefit to the patient or the community. Such an approach only provides the possibility for adverse effects, for example development of antibacterial resistance among bystander bacteria. It is very important to confirm the diagnosis of H. pylori infection. The [13C]urea breath test is the noninvasive method of choice to determine H. pylori status in children and the ideal test for post-therapy testing. There is a need for post-therapy confirmation because of the likelihood of poor outcome for some treatment regimens, which is why post-therapy testing should be the standard of care. There is weak and inconsistent evidence of an association between H. pylori infection and recurrent abdominal pain (RAP) in children, in part because of the unclear definition of RAP in the literature. Therefore, there is still considerable debate regarding the treatment of infected children with RAP.
Collapse
Affiliation(s)
- H M Malaty
- Department of Medicine, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA.
| |
Collapse
|
14
|
Affiliation(s)
- U Blecker
- Division of Pediatric Gastroenterology, Louisiana State University Medical Center, New Orleans 70112, USA.
| | | |
Collapse
|
15
|
|
16
|
Abstract
Drugs used in the treatment of peptic ulcer disease may interact with the renal system in a variety of ways. Since many agents are eliminated by renal excretion, clearance of these agents may be reduced and half-life extended in the presence of renal insufficiency. The histamine H2-receptor antagonists may interfere with renal tubular excretion of creatinine and cationic drugs, resulting in elevated serum concentrations and reduced renal clearance. The prostaglandin E1 analogue misoprostol is used as a cytoprotective agent but has renal effects. The renal effects differ between systems studied. In the rat, misoprostol reduces cyclosporin-induced renal tubular toxicity, whereas in humans it has been shown to attenuate renal allograft rejection. Sucralfate is the aluminium salt of sucrose octasulfate. It permits the absorption of aluminium in amounts similar to aluminium-containing antacids, and toxicity has been demonstrated in the presence of renal insufficiency. Bismuth compounds are used increasingly to treat peptic ulcer disease, and bismuth toxicity has been described in association with renal insufficiency. Aluminium-, calcium- and magnesium-containing antacids are used as oral phosphate binders in patients with renal insufficiency in addition to their usual indications. Cation absorption and accumulation with all of these antacid preparations has been described and may lead to toxicity.
Collapse
Affiliation(s)
- E Burgess
- Department of Medicine, University of Calgary, Alberta, Canada
| | | |
Collapse
|
17
|
Abstract
The clinical approach to the therapy of peptic ulcer disease has changed over the years as our understanding of its pathogenesis has grown. No longer is excess acid production seen as the single cause of ulcer disease; rather, its pathogenesis is viewed as the disturbance of a complex balance of ulcerogenic and protective factors. Today, the clinician's aim is to restore the balance between protective and aggressive factors. Simultaneously, the development of new classes of medications has provided the clinician with the tools to decrease intragastric acidity, neutralize or suppress acid production, and enhance the protective and restorative properties of the mucosa.
Collapse
Affiliation(s)
- K D Katz
- Division of Gastroenterology, University of California, Irvine 92717
| | | |
Collapse
|
18
|
Treiber G, Gladziwa U, Ittel TH, Walker S, Schweinsberg F, Klotz U. Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol Ther 1991; 5:491-502. [PMID: 1793780 DOI: 10.1111/j.1365-2036.1991.tb00518.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We have investigated the absorption and urinary excretion of tripotassium dicitrato bismuthate during a treatment course of 4 weeks in 7 patients with normal renal function (creatinine clearance 115 +/- 29 ml/min; mean +/- S.D.), in 7 patients with impaired renal function (creatinine clearance = 34 +/- 19 ml/min) and in 4 dialysed patients. Following the first dose of tripotassium dicitrato bismuthate (216 mg bismuth b.d.), and after 2 and 4 weeks of treatment (dialysed patients received only 108 mg/b.d.), plasma and urine concentrations of bismuth were monitored for 2 and 24 h, respectively. After stopping therapy plasma and urine concentrations of bismuth were followed for 4 and 6 weeks, respectively. In all three groups of patients small amounts of bismuth (mean values 0.26 to 0.28% of dose) were rapidly (transient mean peak concentrations between 40 and 134 micrograms/L) reached within about 30 to 40 min, absorbed and plasma levels demonstrated a wide intra- and inter-individual variability. Absorption profiles were not altered during the treatment course; however, the trough plasma concentration of bismuth demonstrated an about 3- to 5-fold accumulation (correlated to creatinine clearance) from about 5 micrograms/L to 15 micrograms/L (normal renal function) or to 20-25 micrograms/L (impaired renal function). Pre-study bismuth levels could be detected within 2 to 4 weeks after stopping therapy in all subjects whereas urinary concentrations were still elevated 6 weeks after the course of treatment. Our results indicate that tripotassium dicitrato bismuthate is absorbed in very low amounts during standard therapy. However, dependent on renal function, accumulation to non-toxic levels does occur during a course of treatment. It appears prudent to halve tripotassium dicitrato bismuthate dosage in patients with severe renal insufficiency (creatinine clearance less than or equal to 20 ml/min) to avoid any possible toxic risks. In such patients monitoring of the plasma bismuth concentration might be helpful, especially if longer or repeated treatment is anticipated.
Collapse
Affiliation(s)
- G Treiber
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, FRG
| | | | | | | | | | | |
Collapse
|
19
|
Slikkerveer A, Helmich RB, Edelbroek PM, van der Voet GB, de Wolff FA. Analysis of bismuth in serum and blood by electrothermal atomic absorption spectrometry using platinum as matrix modifier. Clin Chim Acta 1991; 201:17-25. [PMID: 1790623 DOI: 10.1016/0009-8981(91)90020-d] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Bismuth-containing medicines have been used for years, but there is a lack of clinically applicable methods for measuring bismuth in body fluids. We describe a sensitive, accurate and precise method for analysis of bismuth in blood and serum, which is suitable both for monitoring purposes and for further investigations into the biokinetics and safety of bismuth. Bismuth was quantitated with electrothermal atomic absorption spectrometry with Zeeman background correction. In the furnace programme a cool-down step was introduced and platinum was used as a matrix modifier. Recovery for 40 micrograms/l is 93.7 +/- 4.6% (mean +/- SD) from serum and 92.8 +/- 5.4% from blood; within-day precision (n = 10) at 40 micrograms/l is 3.2% for serum and 4.2% for blood. Day-to-day precision at 40 micrograms/l (n = 10) was 4.5% for serum and 4.0% for blood. The detection limit is 0.7 microgram/l for serum and 1.0 microgram/l for blood. Blood samples have to be collected in glass tubes and stored at -20 degrees C.
Collapse
Affiliation(s)
- A Slikkerveer
- Toxicology Laboratory, University Hospital, Leiden, The Netherlands
| | | | | | | | | |
Collapse
|
20
|
Benet LZ. Safety and pharmacokinetics: colloidal bismuth subcitrate. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. SUPPLEMENT 1991; 185:29-35. [PMID: 1957122 DOI: 10.3109/00365529109093217] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Recent studies on oral administration of colloidal bismuth subcitrate suggest that, on average, the blood clearance of bismuth ranges from 50 to 95 ml/min, whereas the bioavailability of bismuth ranges from 0.16 to 0.28%. The higher values in each case assume that biliary clearance is a significant portion of the elimination, whereas the lower values assume only renal clearance. A minimal three-compartment model is necessary to describe the blood and urine excretion time-course data of bismuth. However, the intermediate half-life of 5-11 days represents most of the clearance and elimination. The Hillemand proposal that steady-state blood concentrations of greater than 50 ng/ml and greater than 100 ng/ml should be used as safety and alarm levels, respectively, for bismuth toxicity are probably overcautious, with little expectation of bismuth neurotoxicity associated with steady-state concentrations of 50-100 ng/ml. There is no clinical evidence to suggest that the transient high peak concentrations observed after oral doses of certain bismuth preparations are in any way related to toxicity. Pharmacokinetic theory suggests that initial high peak concentrations would result in only negligible increases in the predicted steady-state blood concentrations and steady-state amounts of drug in the body.
Collapse
Affiliation(s)
- L Z Benet
- Dept. of Pharmacy, University of California, San Francisco 94143-0446
| |
Collapse
|